TrialMolecular genetics and metabolism2023

Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.

Patrick B Deegan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.